Skip to main content

Elevation Oncology, Inc. (ELEV)

NASDAQ: ELEV · IEX Real-Time Price · USD
8.17 0.28 (3.57%)
Oct 26, 2021 1:02 PM EDT - Market open

Company Description

Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations.

We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.

Our lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have recently been identified as oncogenic driver alterations and that we believe have the potential to be therapeutically actionable through targeted HER3 inhibition.

In July 2020, we initiated our Phase 2 CRESTONE trial as the first clinical trial of seribantumab, an anti-HER3 monoclonal antibody, in patients with solid tumors driven by an NRG1 fusion.

We have designed CRESTONE as a tumor-agnostic trial with the potential for registration through an accelerated approval pathway, subject to continued discussions with the FDA.

Elevation Oncology, Inc.
CountryUnited States
Founded2019
IPO DateJun 25, 2021
IndustryBiotechnology
SectorHealthcare
Employees14
CEOShawn Leland, Pharm.D., R.Ph.

Contact Details

Address:
888 Seventh Ave., 12th Floor
New York, NY 10106
United States
Phone716-371-1125
Websiteelevationoncology.com

Stock Details

Ticker SymbolELEV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$16.00
CIK Code1783032
ISIN NumberUS28623U1016
Employer ID84-1771427

Key Executives

NamePosition
Dr. Shawn M. Leland Pharm.D., R.Ph.Founder, President, Chief Executive Officer and Director
Joseph J. Ferra Jr.Chief Financial Officer
Tammy Furlong CPA, P.M.P.Vice President of Finance and Accounting and Secretary
Brian SullivanVice President of Corporate Development